ArticleInternational journal of clinical oncology2021
Efficacy of neoadjuvant chemotherapy in patients with high-risk resectable colorectal liver metastases.
Article in International journal of clinical oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.
- The Role of Preoperative Chemotherapy in the Management of Synchronous Resectable Colorectal Liver Metastases: A Meta-Analysis.Current oncology (Toronto, Ont.) · 2023Pooled it
- Upfront Thermal Ablation versus Neoadjuvant Chemotherapy Followed by Ablation for Oligometastatic Colorectal Liver Metastases: A Propensity Score Matching Analysis.Cardiovascular and interventional radiology · 2026Article
- Impact of time to ablation on survival outcomes in patients with colorectal liver metastases: an inverse probability-weighted cohort study.BMC cancer · 2026Article
- Mature Tertiary Lymphoid Structures Indicate Good Chemotherapy Response and Prognosis in Advanced Colorectal Cancer.Annals of gastroenterological surgery · 2026Article
- Identifying High-risk Patients with Synchronous Colorectal Liver Metastasis: Implications for Preoperative Chemotherapy Selection.Journal of the anus, rectum and colon · 2026Article
- Simple definition of biologically borderline resectable colorectal liver metastases based on early surgical failure.International journal of clinical oncology · 2025Article
- Proposal of "borderline resectable" colorectal liver metastases based on analysis of risk factors for early surgical failure.Surgery today · 2025Article
- ASO Author Reflections: Optimizing Treatment Sequencing in Synchronous Resectable Colorectal Liver Metastases.Annals of surgical oncology · 2024Article
- Perioperative Chemotherapy is Associated with Superior Overall Survival in Patients with Synchronous Colorectal Liver Metastases.Annals of surgical oncology · 2023Article
- Article
- Clinical outcomes of neoadjuvant chemotherapy for resectable colorectal liver metastasis with intermediate risk of postoperative recurrence: A multi-institutional retrospective study.Annals of gastroenterological surgery · 2023Article
- Survival Study: International Multicentric Minimally Invasive Liver Resection for Colorectal Liver Metastases (SIMMILR-2).Cancers · 2022Article
- Efficacy of neoadjuvant chemotherapy for initially resectable colorectal liver metastases: A retrospective cohort study.World journal of gastrointestinal oncology · 2022Article
- Neoadjuvant chemotherapy improves overall survival in resectable colorectal liver metastases patients with high clinical risk scores-- A retrospective, propensity score matching analysis.Frontiers in oncology · 2022Article
- Clinical Significance of Controlling Nutritional Status (CONUT) Score in Patients With Colorectal Liver Metastases After Hepatectomy.In vivo (Athens, Greece)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe role of preoperative neoadjuvant chemotherapy (NAC) in patients with resectable colorectal liver metastases (CRLM) remains undetermined. This study aimed to assess the efficacy of NAC in patients with resectable CRLM, especially in high-risk subgroups for recurrence, with special reference to synchronicity and the CRLM grade in the Japanese classification system.
methodsA retrospective analysis of a multi-institutional cohort who was diagnosed with resectable CRLM was performed. CRLM was classified into three grades (A, B, and C) according to the combination of H stage (H1: ≤ 4 lesions and ≤ 5 cm, H2: ≥ 5 lesions or > 5 cm, H3: ≥ 5 lesions and > 5 cm), nodal status of the primary tumor (pN0/1: ≤ 3 metastases, pN2: ≥ 4 metastases), and the presence of resectable extrahepatic metastases.
resultsAmong 222 patients with resectable CRLM, 97 (43.7%) had synchronous CRLM. The surgical failure-free survival (SF-FS) of patients with synchronous CRLM (without NAC) was significantly worse than that of patients with metachronous CRLM (P = 0.0264). The SF-FS of patients with Grade B/C was also significantly worse than that of Grade A (P = 0.0058). Among the 53 patients with synchronous and Grade B/C CRLM, 31 were assigned to NAC, and all of them underwent liver surgery. In this high-risk subgroup, the SF-FS and OS in the NAC group were significantly better than those in the upfront surgery group (P < 0.0001 and P = 0.0004, respectively).
conclusionsPatients with synchronous and Grade B/C CRLM could be good candidates for indication of NAC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.